BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price target remains the same with $150.00. Don't Miss our ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00. The company’s shares closed last Friday at $99.72. Don't ...

BioNTech SE (BNTX) has released an update. BioNTech SE is entering a new phase of growth, focusing on expanding its oncology ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

Shares of BioNTech (BNTX) gained in pre-market trading after the company reported better-than-expected Q3 earnings. The biotech company’s earnings increased by 22.7% to €0.81 ($0.89 ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

View upcoming earnings forecasts and in-depth analysis of company forecasts.